Exhibit 99.1 Media Contact October 28, 2024 Polly Manuel, 205 969-4532 polly.manuel@encompasshealth.com Investor Relations Contact Mark Miller, 205 970-5860 mark.miller@encompasshealth.com Encompass Health reports results for third quarter 2024 Increases full-year guidance BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the third quarter ended September 30, 202 ...

Analysts on Wall Street project that Encompass Health (EHC) will announce quarterly earnings of $0.94 per share in its forthcoming report, representing an increase of 9.3% year over year. Revenues are projected to reach $1.33 billion, increasing 10% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's ear ...

Group 1 - Encompass Health Corporation announced the redemption of $100 million of its 5.75% senior notes due 2025, with a redemption date set for November 21, 2024, at a price of 100.0% of par plus accrued interest [1] - The company plans to utilize cash on hand for the redemption and anticipates recording an approximate $0.2 million loss on early extinguishment of debt in Q4 2024 [1] Group 2 - Encompass Health is the largest owner and operator of rehabilitation hospitals in the United States, with 165 hospitals across 38 states and Puerto Rico [2] - The company is recognized for providing high-quality rehabilitative care and has received accolades such as being ranked among Fortune's World's Most Admired Companies [2]

Core Insights - Encompass Health (EHC) is currently viewed as a better investment option compared to Astrana Health, Inc. (ASTH) based on Zacks Rank and earnings estimate revisions [1][3] Valuation Metrics - EHC has a forward P/E ratio of 22.93, while ASTH has a significantly higher forward P/E of 45.94 [2] - EHC's PEG ratio stands at 1.46, indicating a more favorable valuation relative to its expected earnings growth, compared to ASTH's PEG ratio of 2.29 [2] - EHC's P/B ratio is 3.88, which is lower than ASTH's P/B ratio of 4.32, suggesting EHC is more reasonably priced in terms of its book value [2] Value Grades - EHC has received a Value grade of A, while ASTH has a Value grade of C, reflecting EHC's stronger valuation metrics and improving earnings outlook [3]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Encompass Health (EHC) driven by higher revenues, with the earnings report expected on October 28, 2024, being crucial for stock price movement based on actual results compared to estimates [1] Earnings Estimates - Encompass Health is projected to report quarterly earnings of $0.94 per share, reflecting a year-over-year increase of +9.3% [2] - Expected revenues for the quarter are $1.33 billion, which represents a 10% increase from the same quarter last year [2] Estimate Revisions - The consensus EPS estimate has been revised 0.04% lower in the last 30 days, indicating a slight reassessment by analysts [3] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Encompass Health is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.13%, suggesting a bullish outlook from analysts [4][6] - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [5] Historical Performance - In the last reported quarter, Encompass Health exceeded the expected earnings of $1.01 per share by delivering $1.11, resulting in a surprise of +9.90% [7] - The company has beaten consensus EPS estimates in all of the last four quarters [7] Conclusion - Encompass Health is positioned as a compelling candidate for an earnings beat, with a positive Earnings ESP and a Zacks Rank of 2, although other factors should also be considered before making investment decisions [8]

Core Viewpoint - Encompass Health (EHC) is positioned well to continue its trend of beating earnings estimates, supported by a strong history of performance in the Zacks Medical - Outpatient and Home Healthcare industry [1] Group 1: Earnings Performance - Encompass Health has consistently surpassed earnings estimates, achieving an average beat of 15.17% over the last two quarters [1] - In the most recent quarter, the company reported earnings of $1.11 per share against an expectation of $1.01, resulting in a surprise of 9.90% [1] - For the previous quarter, the consensus estimate was $0.93 per share, while the actual earnings were $1.12, leading to a surprise of 20.43% [1] Group 2: Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Encompass Health, with a positive Zacks Earnings ESP indicating a strong likelihood of an earnings beat [2] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced a positive surprise nearly 70% of the time [2] - Encompass Health currently has an Earnings ESP of +0.13%, suggesting analysts are optimistic about the company's earnings prospects [3] Group 3: Upcoming Earnings Report - The next earnings report for Encompass Health is expected to be released on October 28, 2024 [3]

Encompass Health (EHC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Individual investo ...

Encompass Health Corporation (EHC) has been gaining on growing patient admissions, commendable expansion initiatives and a robust cash position. A solid 2024 business outlook also reinforces investors' confidence in the stock. EHC's Zacks Rank & Price Performance Encompass Health currently carries a Zacks Rank #3 (Hold). The stock has gained 43.4% in the past year compared with the industry's 34.5% growth. The Zacks Medical sector has rallied 13.1% and the S&P 500 composite increased 33.4% in the same time ...

Encompass Health Rehabilitation Hospital of Fort Mill provides essential rehabilitative services that help patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions regain function and independence. Patients receive a minimum of three hours of intensive therapy for five days each week, frequent physician visits and 24-hour nursing care. "The need for inpatient rehabilitative care in the Fort Mill and greater Charlotte area has been growing rapidly" ...

Encompass Health Corporation (EHC) shares have shot up 39.4% in the year-to-date period, outperforming the industry's return of 17.9% and the S&P 500 Index's rise of 18.4%. Growing patient volumes and impressive growth-related initiatives appear to have catalyzed this bullishness. Currently priced at $93.05, the stock is just 1.4% below its 52-week high of $94.38. This proximity underscores investor confidence and market optimism about this healthcare company's prospects. It has the ingredients for further ...